Company Overview of Interface Biologics, Inc.
Interface Biologics, Inc. develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. The company’s technology focuses on anti-thrombogenic additives and programmable combination drug delivery devices. It provides Endexo technology for blood contacting medical devices that addresses thrombosis problems; Epidel anti-infective polymers that allows for pharmaceuticals to be integrated directly into the medical device; and Kinesyx bioactive surface pacifying oligomers. The company was founded in 2001 and is headquartered in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2001
Key Executives for Interface Biologics, Inc.
Interface Biologics, Inc. Key Developments
Similar Private Companies By Industry
|Genova Biotherapeutics, Inc.||Americas|
|CanPro Ingredients Ltd.||Americas|
|Alethia BioTherapeutics Inc.||Americas|
|Pacific Pharma Technologies, Inc.||Americas|
|Chemokine Therapeutics Corporation||Americas|
Recent Private Companies Transactions
January 13, 2015
To contact Interface Biologics, Inc., please visit www.interfacebiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.